5,724 Shares in Revolution Medicines, Inc. $RVMD Acquired by Quantbot Technologies LP

Posted by Brian Himes on Aug 26th, 2026

Quantbot Technologies LP bought a new stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 5,724 shares of the company’s stock, valued at approximately $1,072,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Contravisory Investment Management Inc. purchased a new position in shares of Revolution Medicines during the 2nd quarter worth $32,000. Johnson Financial Group Inc. purchased a new stake in shares of Revolution Medicines in the 2nd quarter worth $37,000. Silvant Capital Management LLC purchased a new stake in shares of Revolution Medicines in the 2nd quarter worth $41,000. Rakuten Securities Inc. bought a new position in Revolution Medicines in the 2nd quarter worth $66,000. Finally, Harbor Investment Advisory LLC bought a new position in Revolution Medicines in the 2nd quarter worth $70,000. 94.34% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Revolution Medicines

In other Revolution Medicines news, CFO Jack Anders sold 20,000 shares of the business’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $168.33, for a total value of $3,366,600.00. Following the sale, the chief financial officer owned 123,269 shares in the company, valued at $20,749,870.77. The trade was a 13.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Stephen Michael Kelsey sold 4,175 shares of the stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $156.12, for a total transaction of $651,801.00. Following the transaction, the insider directly owned 291,876 shares of the company’s stock, valued at $45,567,681.12. This trade represents a 1.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 212,497 shares of company stock valued at $38,206,486 in the last ninety days. Corporate insiders own 7.60% of the company’s stock.

Revolution Medicines Trading Down 0.1%

Shares of RVMD stock opened at $211.38 on Wednesday. Revolution Medicines, Inc. has a 52-week low of $35.62 and a 52-week high of $220.34. The company has a debt-to-equity ratio of 0.40, a quick ratio of 11.38 and a current ratio of 11.38. The firm has a market capitalization of $45.31 billion, a PE ratio of -23.97 and a beta of 1.39. The stock has a fifty day simple moving average of $190.11 and a two-hundred day simple moving average of $146.46.

Revolution Medicines (NASDAQ:RVMD – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($3.06) EPS for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same quarter last year, the company earned ($1.31) earnings per share. On average, analysts predict that Revolution Medicines, Inc. will post -8.82 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. Needham & Company LLC lifted their target price on Revolution Medicines from $236.00 to $240.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Piper Sandler raised their price objective on Revolution Medicines to $172.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. HC Wainwright reaffirmed a “buy” rating and set a $195.00 price objective on shares of Revolution Medicines in a research report on Monday, July 6th. Truist Financial boosted their price objective on Revolution Medicines from $210.00 to $231.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Finally, Guggenheim increased their target price on shares of Revolution Medicines from $235.00 to $240.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Revolution Medicines currently has a consensus rating of “Moderate Buy” and an average target price of $167.89.

View Our Latest Stock Report on Revolution Medicines

Revolution Medicines Company Profile

(Free Report)

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.